Courses

Update on New and Emerging CD-20 Targeted Therapeutics for the Treatment of Patients with Multiple Sclerosis

Update on New and Emerging CD-20 Targeted Therapeutics for the Treatment of Patients with Multiple Sclerosis

This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight new and emerging CD-20 targeted therapeutics for the treatment of patients with multiple sclerosis (MS). The expert faculty, Dr. Mark Freedman, will first review current clinical trial data for CD-20 targeted therapies to improve long-term patient ...
View Course

Accurate and Effective Imaging in the Diagnosis and Management of Hypertrophic Cardiomyopathy: A Practical Approach

Accurate and Effective Imaging in the Diagnosis and Management of Hypertrophic Cardiomyopathy: A Practical Approach

Accurate diagnosis is vital for the successful management of patients with HCM.  Mistakes and delays in diagnosis are common. Hypertrophic cardiomyopathy commonly "masquerades" as asthma, anxiety, mitral prolapse, and coronary artery disease. However, once properly diagnosed, patients with HCM can be effectively managed to improve both symptoms and survival. Today, the diagnosis of HCM relies on the identification of increased ...
View Course
Anti-CD19 Therapeutics to Manage Patients with Anti-AQP4 Antibody Positive Neuromyelitis Optics Spectrum Disorder

Anti-CD19 Therapeutics to Manage Patients with Anti-AQP4 Antibody Positive Neuromyelitis Optics Spectrum Disorder

This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight the use of anti-CD19 therapeutics to manage patients with anti-AQP4 antibody positive neuromyelitis optica spectrum disorder (NMOSD). The expert faculty, Prof. Hans-Peter Hartung, will first analyze the methodologies for a timely and accurate diagnosis of NMOSD ...
View Course

Advances in the Management of Patients with Diabetic Kidney Disease in the Setting of Type 2 Diabetes

Advances in the Management of Patients with Diabetic Kidney Disease in the Setting of Type 2 Diabetes

New, actionable data on the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors was released at several major meetings in 2022, culminating in November at ASN/Kidney Week that herald signal advances in the management of DKD/T2D. These new data and an expert contextualization of their role in contemporary practice is the basis of this webcast. Nephrologists, diabetologists, other internists, primary care providers, ...
View Course
Specific Reversal of Anti-Factor Xa DOAC Anticoagulation: Incorporating Latest Data into Practice and Institutional Protocols

Specific Reversal of Anti-Factor Xa DOAC Anticoagulation: Incorporating Latest Data into Practice and Institutional Protocols

Severe and life-threatening hemorrhage in patients receiving anti-FXa DOACs is unusual; especially for the most-feared bleeding complication, ICH, events are significantly less common than for patients on vitamin K antagonists (VKA).  Still, these events occur, and there is a need for specific, timely, evidence-guided, and multimodal management of DOAC-treated patients with hemorrhage to avoid worsening morbidity, excessive cost and length ...
View Course
Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC

Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC

This CME program, derived from content presented at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland, will highlight the utilization of immunohistochemistry testing, biomarkers, and targeted therapeutics to optimize outcomes in patients with non-small cell lung cancer (NSCLC). The expert faculty, led by Dr. Solange Peters, will first review the scientific advances for the identification of NSCLC biomarkers, and associated ...
View Course

Scientific Update on Bruton Tyrosine Kinase Inhibitors to Improve Outcomes for Patients with Multiple Sclerosis

Scientific Update on Bruton Tyrosine Kinase Inhibitors to Improve Outcomes for Patients with Multiple Sclerosis

This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will delve into a scientific update on Bruton tyrosine kinase inhibitors (BTKi) to improve outcomes for patients with multiple sclerosis (MS). The expert faculty, Dr. Benjamin Greenberg, will first review recent clinical trial data for BTK inhibitor therapeutics to treat patients with MS ...
View Course

Strategies to Identify and Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis

Strategies to Identify and Manage Spasticity and Related Symptoms in Patients with Multiple Sclerosis

This CME program, derived from content presented at the 2022 Joint Pre-ECTRIMS Workshop in Amsterdam, the Netherlands, will highlight strategies to identify and manage spasticity in patients with multiple sclerosis (MS). The expert faculty, Dr. Fred D. Lublin, will first review the unmet needs of multiple sclerosis patients with spasticity. Next, an analysis of current and emerging clinical trial data ...
View Course

Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to Improve Outcomes for Patients with Advanced Ovarian Cancer

Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to Improve Outcomes for Patients with Advanced Ovarian Cancer

This CME/CE program will highlight the application of poly (ADP-ribose) polymerase (PARP) inhibitors to improve outcomes for patients with advanced ovarian cancer. The expert faculty, led by Dr. Don Dizon, will first review updates to the National Comprehensive Care Network (NCCN) evidence-based guidelines. Next, an analysis of current and emerging clinical trial data of PARP Inhibitors will be discussed. Following, ...
View Course

Case Studies in Optimal Management of Anti-FXa-DOAC-Associated Intracranial Hemorrhage: Specific vs Nonspecific Anticoagulant Reversal

Case Studies in Optimal Management of Anti-FXa-DOAC-Associated Intracranial Hemorrhage: Specific vs Nonspecific Anticoagulant Reversal

This CME program is derived from content presented at the 8th European Stroke Organization Conference (ESOC 2022). This educational activity, chaired by Dr. Thorsten Steiner, will review optimal management strategies of patients with anti-FXa-DOAC-associate Intracranial Hemorrhage (ICH). The worldwide utilization of DOACs for a number of different indications has continuously increased over the past decade, and while the anti-FXa DOACS ...
View Course